FIELD: biotechnology.
SUBSTANCE: disclosed is an oncolytic virus containing a nucleic acid molecule built into its genome, which codes one or more modulators of an immunological control point. Said oncolytic virus is an oncolytic vaccine of vaccinia virus defective in thymidine kinase (TK) as a result of inactivating mutations in the J2R virus gene and defective as to activity of ribonucleotide reductase (RR) as a result of inactivating mutations in the viral gene I4L. Said one or more immunological control point modulators comprises an anti-PD-1 antibody. Described is an anti-tumour pharmaceutical composition containing said virus.
EFFECT: invention can be used for treating proliferative diseases, such as cancer diseases.
24 cl, 6 dwg, 1 ex
| Title |
Year |
Author |
Number |
| COMBINATION OF ONCOLYTIC VIRUS WITH MODULATORS OF IMMUNOLOGICAL CONTROL POINTS |
2015 |
- Tsitfogel Lorans
- Previll Ksave
- Fend Letitsiya
|
RU2705780C2 |
| M2-DEFECTIVE POXVIRUS |
2019 |
- Klyajnpeter, Patritsia
- Marshan, Zhan-Batist
- Remi, Kristell
- Shmitt, Doris
|
RU2819245C2 |
| ONCOLYTIC ADENOVIRUSES ENCODING BISPECIFIC ANTIBODIES, AS WELL AS METHODS AND APPLICATIONS ASSOCIATED THEREWITH |
2016 |
- Siurala, Mikko
- Liikanen, Ilkka
- Tahtinen, Siri
- Parviainen, Suvi
- Hemminki, Akseli
|
RU2725799C2 |
| CONSTRUCTION OF OBLIGATE VECTOR BASED ON ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) AND CONSTRUCTS FOR CANCER THERAPY |
2016 |
- Chzhou, Grejs Goin
- Chen, Syaotsin
- Lyu, Syantsze
|
RU2751236C2 |
| ADENOVIRAL VECTORS AND RELATED METHODS AND APPLICATIONS |
2009 |
- Khemminki Akseli
- Kanerva Anna
- Cherullo Vinchentso
- Pesonen Sari
|
RU2520823C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER |
2016 |
- Shaw, Steven
- Westby, Michael
- Galili, Uri
|
RU2720984C2 |
| ANTICANCER COMPOSITION CONTAINING TUMOR-SPECIFIC ONCOLYTIC ADENO VIRUS AND INHIBITOR OF CONTROL POINT OF IMMUNE RESPONSE |
2018 |
|
RU2777523C2 |
| ANTICANCER COMPOSITION CONTAINING A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE RESPONSE CONTROL POINT INHIBITOR |
2018 |
|
RU2740713C1 |
| COMBINATION THERAPY FOR TREATING CANCER WITH POXVIRUS EXPRESSING TUMOUR ANTIGEN AND ANTAGONIST AND/OR AGONIST OF IMMUNE CHECKPOINT INHIBITOR |
2014 |
- Rauntri, Rajan
- Foj, Syuzan
- Mendl, Stefani
- Delker, Alen
|
RU2714142C2 |
| NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE |
2019 |
- Frendeus, Bern
- Tejge, Ingrid
- Zemrikh, Monika
- Mortensson, Linda
- Kholmkvist, Petra
- Marshan, Zhan-Batist
- Silvestr, Natali
|
RU2802450C2 |
